Skip to main content
MyPeptideMatch
Reviewed by MyPeptideMatch Editorial TeamLast reviewed October 2026Updated October 2026

Cerebrolysin Dosing Protocol: 60 mg Vial & Trial Doses

Cerebrolysin (porcine brain peptide mixture): the IV doses used in clinical trials, the community-reported subcutaneous schedule for the 60 mg research vial (often sold as CBL60), reconstitution math, and what the evidence shows.

Quickstart highlights

Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids made by controlled digestion of pig brain proteins.

  • Two different products: the licensed ampoule solution used in trials (dosed in mL, IV, in hospital) and the 60 mg lyophilized research vial, often sold as CBL60 (no trial data).
  • Trial doses: 30 mL daily IV for 10–21 days in stroke; 20 mL daily in vascular dementia; 50 mL daily, then 10 mL courses, in brain injury; 10–60 mL in Alzheimer's.
  • Research vial math: 60 mg + 6 mL bac water = 10 mg/mL, so 60 mg = 6 mL.
  • The subcutaneous 60 mg once- or twice-weekly schedule is community-reported; no trial used subcutaneous injection.
  • Cochrane (2023) found no reduction in deaths after stroke. See the Cerebrolysin peptide page for the evidence.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1——IV infusion daily x 10 daysFrom clinical trials, not community-reported: 20 mL of the licensed ampoule solution by IV infusion once daily was used in a 242-patient vascular dementia trial (PMID 20656516); stroke trials used 30 mL daily for 10–21 days. Given in hospital under medical supervision. This row is in mL of the licensed solution and does not apply to the 60 mg research vial.
2-12——Subcutaneous 60 mg 1–2x weeklyCommunity-reported, not from a trial: 60 mg of the research vial subcutaneously, quoted as once or twice weekly; at 10 mg/mL that is 6 mL per dose. No trial used subcutaneous injection or the lyophilized vial, and there is no published conversion between 60 mg of powder and the mL trial doses.

Your free Cerebrolysin tracker

  • Dose reminders
  • Injection logging
  • Cycle progress
Create free account Already have one? Sign in

Reconstitution steps

  1. Add 6 mL bacteriostatic water to the 60 mg lyophilized vial, running it slowly down the vial wall.
  2. Swirl gently until dissolved; do not shake.
  3. Final concentration: 10 mg/mL. At 10 mg/mL, 60 mg = 6 mL.
  4. This math applies only to the research powder. Trial doses were mL of the licensed ampoule solution given by IV infusion in hospital, and they do not convert to this vial.
  5. Label with the date; refrigerate at 2–8 °C and use within 28 days.

Supplies needed

See your prescribing clinician for a supplies list.

Protocol overview & cycle notes

Reference schedule and reconstitution math for a 60 mg Cerebrolysin research vial, set alongside the IV doses used in clinical trials. Trial doses are mL of the licensed ampoule solution given in hospital and do not convert to the research vial; the subcutaneous schedule is community-reported, not from a trial.

Off-cycle: Not established for the research vial. Trials gave single courses of 10–21 days; the traumatic brain injury trials added two 10-day courses of 10 mL daily after the first course, and the vascular dementia trial gave two treatment cycles. No study has tested breaks between courses.

Storage & handling

Lyophilized: store below 25 °C, away from light. Reconstituted: refrigerate at 2–8 °C and use within 28 days.

Injection & tracking tips

  • In trials, Cerebrolysin was given by IV infusion in hospital. IV infusion is not a home procedure.
  • No trial used subcutaneous injection. A 60 mg dose at 10 mg/mL is 6 mL, a large volume for one subcutaneous site; community protocols split it across 2–3 sites of about 2 mL.
  • Rotate injection sites and use a new sterile syringe every time.
  • No study has tested Cerebrolysin combined with Semax, BPC-157 or other nootropics, so combination protocols are untested.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • If used for a diagnosed condition, ask your clinician to record a cognitive score (for example MoCA) at baseline and after each course.
  • For stroke or dementia, track activities of daily living with your care team.
  • Record any reaction during or after each injection or infusion and report it to the supervising clinician.
Log your cycle in the calculator →

How this works & references

Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids made by controlled digestion of pig brain proteins. It is proposed to act like neurotrophic factors, but a 2015 mass spectrometry analysis of Cerebrolysin bought online found 638 peptides, mostly fragments of tubulin, actin and myelin basic protein, and no fragments of BDNF, NGF, GDNF or CNTF. The 2023 Cochrane review of seven stroke trials (1,773 people) found it probably does not reduce deaths and may increase non-fatal serious adverse events. The largest trial, CASTA (1,070 people, 30 mL daily IV for 10 days), was neutral on its main endpoint. The 2019 Cochrane review of vascular dementia rated the evidence very low quality.

Sources

Frequently asked questions

What is the Cerebrolysin 60 mg dosage?
No trial used a 60 mg vial, so there is no evidence-based dose for it. The schedule on this page, 60 mg subcutaneously once or twice weekly, is community-reported. Trials dosed the licensed solution in mL by IV infusion. One registered trial describes that solution as 215.2 mg per mL, so 60 mg would be about 0.3 mL of it if the materials were the same, which has not been shown.
What is CBL60?
CBL60 is the product code several research peptide vendors use for a 60 mg vial of lyophilized Cerebrolysin powder. It is the vial this page covers, not a separate peptide, and not the licensed solution used in clinical trials. The reconstitution math and schedule above apply to it the same way.
What dose of Cerebrolysin was used in clinical trials?
Trials gave the licensed ampoule solution by IV infusion in hospital: 30 mL daily for 10 days in acute stroke and for 21 days with rehabilitation; 20 mL daily in vascular dementia; 50 mL daily for 10 days, then two 10-day courses of 10 mL daily, in traumatic brain injury. An Alzheimer's trial compared 10, 30 and 60 mL, and 10 mL did best on cognition.
Can Cerebrolysin be injected subcutaneously?
There is no clinical evidence for it. None of the 43 Cerebrolysin studies on ClinicalTrials.gov (searched October 2026) used subcutaneous injection, and PubMed results for subcutaneous Cerebrolysin are animal studies. Human trials used IV infusion, and a few registered trials used intramuscular injection.
How do you reconstitute a 60 mg Cerebrolysin vial?
Adding 6 mL of bacteriostatic water gives 10 mg/mL, so the whole 60 mg vial is 6 mL. That math helps with measuring the research powder accurately. It does not make the dose equivalent to any trial dose.
How is Cerebrolysin given IV?
In trials it was given once daily by IV infusion in hospital, for example 30 mL a day for 10 consecutive days in the CASTA stroke trial. IV infusion is a medical procedure, not something to do at home, and the trials used the licensed solution, not research powder.
Is Cerebrolysin FDA-approved?
No. It is used as a licensed medicine in some countries, mainly in Eastern Europe and Asia, but it is not approved by the FDA, and no registered Cerebrolysin trial lists a US site.

Related protocols

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.